CAMP logo

CAMP4 THERAPEUTICS CORP

CAMPNASDAQ
πŸ† #3344 by market capEarnings Mar 3US Equity
β€”β€”
Quote unavailable
πŸ””
Track CAMP
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$238M
Small Cap
πŸ“ˆRevenue Growth (YoY)
5.6%
Slowing
πŸ“ŠGross Margin
35.8%
Healthy
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
64
Fair
No chart data available for CAMP.

Trading Snapshot

Day Range
β€”
52-Week Range
$2.90 – $7.75
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
62.8M
Next Earnings
2027-03-03

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$2M
P/E Ratio
β€”
P/S Ratio
0.0x
EPS (TTM)
$-2.20
Dividend Yield
β€”
Dilution (1yr)
+166.1%
CAMP logo

CAMP4 THERAPEUTICS CORP

CAMP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3Mβ–² +436.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
53.1%β–Ό βˆ’46.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$52Mβ–Ό βˆ’1.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$30Mβ–Ό βˆ’35.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
51.9Mβ–² +166.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$108Mβ–² +$52M YoY
StockOtter Β· stockotter.space

About CAMP4 THERAPEUTICS CORP

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100
Analyst data unavailable.

Latest News & Updates

News unavailable.